Tamsulosin Hydrochloride Capsule
Product Images NDC 68071-5118

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tamsulosin Hydrochloride (NDC 68071-5118). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 5118 1)

Label for Tamsulosin Hydrochloride 0.4 mg capsules by NuCare Pharmaceuticals, Inc. The package contains 100 capsules. The label includes NDC 68071-5118-1, product number R1630100, and storage instructions to keep at 68-77°F. It features a warning to keep out of reach of children and references a manufacturer's label for full ingredient listing.*

FDA Label Image

Figure 1 Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-dose Administration Of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted And Fed Conditions (n=8) (Tamsulosin Fig1)

A line graph showing mean plasma tamsulosin hydrochloride concentrations over time after a single dose of 0.4 mg capsules. The graph compares concentrations under fasted and fed conditions across 36 hours, with plasma concentration on the y-axis (ng/mL) and time on the x-axis (hours).*

FDA Label Image

Figure 2a Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 1 (Tamsulosin Fig2)

A line graph showing the mean change from baseline in total AUA symptom score over treatment duration in weeks. Three treatment groups are compared: 0.8 mg, 0.4 mg, and placebo. The graph includes data points at multiple weeks up to 13 weeks and a last observation carried forward (LOCF) endpoint, illustrating symptom score improvement trends for each group over time.*

FDA Label Image

Figure 2b Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 2 (Tamsulosin Fig3)

Line graph showing mean change from baseline in total AUA Symptom Score (0 to 35) over 13 weeks of treatment in Study 2. The x-axis represents duration of treatment in weeks with data points at 0, 1, 2, 5, 9, and 13 weeks. The y-axis shows mean change values from 0 to -11. Three treatments are compared: 0.8 mg, 0.4 mg, and placebo, with 0.8 mg and 0.4 mg showing greater reductions in symptom scores than placebo over time.*

FDA Label Image

Figure 3a Mean Increase In Peak Urine Flow Rate (ml/sec) Study 1 (Tamsulosin Fig4)

A line graph titled 'Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 1' showing mean change in flow rate over treatment duration in weeks. It compares three groups: 0.8 mg dose (circles), 0.4 mg dose (triangles), and placebo (squares). The x-axis represents duration of treatment in weeks, y-axis represents mean change in mL/sec. Data points include baseline, weeks 0 to 13, and LOCF, illustrating higher mean increases in flow rate for both doses versus placebo throughout the study.*

FDA Label Image

Figure 3b Mean Increase In Peak Urine Flow Rate (ml/sec) Study 2 (Tamsulosin Fig5)

A line graph titled 'Figure 3B Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 2' depicting mean change in urine flow rate over treatment duration in weeks. The graph compares three treatments: 0.8 mg, 0.4 mg, and placebo, showing changes on the y-axis (mean change in mL/sec) against treatment weeks on the x-axis. Sample sizes at each time point are listed below the x-axis.*

FDA Label Image

Chemical Structure (Tamsulosin Str)

Chemical structure of Tamsulosin Hydrochloride. The diagram shows the molecular arrangement including aromatic rings, functional groups such as sulfonamide, ether, and amine, and the hydrochloride salt form indicated by HCl.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.